Browse Category

NYSE:CNC 4 October 2025 - 29 July 2026

For live price, interactive charts, financials and the latest market data, visit Google Finance.
UnitedHealth Stock Jumps as Centene Results Put Insurer Turnaround Back in Play

UnitedHealth Stock Jumps as Centene Results Put Insurer Turnaround Back in Play

UnitedHealth Group Incorporated saw its shares jump roughly 4% to $369.41 early Tuesday afternoon, lifted alongside other U.S. health insurers after Centene issued another profit outlook boost. Centene surged more than 14%. Humana and CVS Health picked up gains as well, as the latest guidance stoked hopes that the sector’s medical-cost crunch could be loosening its grip.
28 April 2026
·····
Healthcare stocks in focus: Molina shock, FDA “copycat” warning and XLV set up Monday’s trade

Healthcare stocks in focus: Molina shock, FDA “copycat” warning and XLV set up Monday’s trade

Molina Healthcare plunged 25.5% to $131.72 on Friday, after the company told investors to brace for at least $5 in adjusted earnings per share in 2026—missing what analysts had penciled in. The Medicaid specialist also plans to pull out of Medicare Advantage Part D prescription drug plans starting in 2027. CEO Joseph Zubretsky described 2026 as a “trough year” for Medicaid margins. Molina attributed the trimmed outlook to losses from its Part D business and a fresh Florida Medicaid contract, each dragging estimates by $1 and $1.50 per share. The Health Care Select Sector SPDR Fund didn’t follow Molina lower, instead picking up 1.8% to finish at $157.71.
7 February 2026
···
Centene (CNC) Stock News, Forecasts and Analysis on December 12, 2025: Why Shares Rebounded Near $40 and What Comes Next

Centene (CNC) Stock News, Forecasts and Analysis on December 12, 2025: Why Shares Rebounded Near $40 and What Comes Next

Centene Corporation is ending 2025 with investors focused on a familiar mix of catalysts: Medicaid margin repair, ACA Marketplace volatility, and Washington policy risk. The stock’s latest pop has been driven by a fresh analyst price-target increase, but the broader narrative remains shaped by a dramatic mid-year guidance reset and ongoing uncertainty around Affordable Care Act premium subsidies that are scheduled to expire December 31, 2025. MarketBeat+2Reuters+2
12 December 2025
·
Centene (CNC) Slides on ACA-Subsidy Uncertainty as Wellcare Expands in Texas and Ambetter Adds South Carolina Plans — Nov. 10, 2025

Centene (CNC) Slides on ACA-Subsidy Uncertainty as Wellcare Expands in Texas and Ambetter Adds South Carolina Plans — Nov. 10, 2025

In posts over the weekend, President Donald Trump called for redirecting “hundreds of billions” in ACA subsidy funds directly to consumers, rather than to insurers. By early Monday, managed-care stocks with ACA exposure, including Centene, were lower in premarket trading. Reuters notes the comments land amid a 40‑day federal government shutdown and renewed debate over enhanced ACA subsidies set to expire Dec. 31, a program that has helped double ACA enrollment to ~24 million since 2021. Reuters
10 November 2025
·
Elevance Health Stock Soars on Massive Q3 Earnings Beat – What It Means for Investors

Elevance Health Stock Soars on Massive Q3 Earnings Beat – What It Means for Investors

Elevance Health posted strong third-quarter 2025 results, significantly outperforming market expectations on both profit and revenue. Adjusted earnings came in at $6.03 per share, well above the ~$4.95 analysts predictedinvesting.com. Likewise, revenue for the quarter reached $50.1 billion, surpassing the $49.3 billion consensus and growing 12% year-over-yearinvesting.com. This robust growth was fueled by higher premium yields and an expanding customer base – particularly gains in Medicare Advantage enrollments – along with contributions from recent acquisitions in Elevance’s Carelon health services unittradingview.com. These factors combined to help Elevance smash its Q3 forecasts, showcasing strong demand and pricing power in its health benefits business.
21 October 2025
····
Record Highs, AI Hype, and a Shutdown: Key Takeaways from U.S. Stock Markets (Oct 3–4, 2025)

Record Highs, AI Hype, and a Shutdown: Key Takeaways from U.S. Stock Markets (Oct 3–4, 2025)

Wall Street’s major indexes extended their rally into the first days of October, defying the political gridlock in Washington. On Friday, October 3, the benchmark S&P 500 edged up less than 0.1% to 6,715.79, just enough to mark a record closing high reuters.com. The Dow Jones Industrial Average climbed 0.5% to 46,758.28, also a record finish reuters.com. Meanwhile, the Nasdaq Composite slipped about –0.3% to 22,780.5, snapping its winning streak as some tech shares weakened reuters.com. Notably, all three indexes had hit intraday all-time highs during Friday’s session before a bit of profit-taking into the close reuters.com.
4 October 2025
····

Google Preferred Source

Follow on Google News
Add as preferred source Open in Google News
TS2 TECH • AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 BUY ON WEAKNESS

Visa

NYSE: V 93 / 100

Visa delivered more than just a headline beat this quarter, with spending, payment volume, cross-border volume, and processed transactions each rising by double digits.…

#2 BUY

Hubbell

NYSE: HUBB 92 / 100

Hubbell boosted its sales and profit outlook following strong double-digit organic growth. Although shares dipped 2.8% on Tuesday, the company’s operating performance is on…

#3 BUY ON PULLBACK

Xylem

NYSE: XYL 90 / 100

Xylem reported $3.1 billion in orders last quarter, providing clearer visibility than the modest 2% revenue growth indicates. Demand for water treatment is rising…

#4 ACCUMULATE

Ford

NYSE: F 86 / 100

Ford’s updated cash forecast stands out compared to its market capitalization. Strong truck pricing, product mix, and cost discipline supported this quarter. However, the…

#5 TACTICAL BUY

SoFi

NASDAQ: SOFI 82 / 100

SoFi boosted its revenue outlook following record growth in members, loan originations, and profit. Lending remains robust, but technology platform revenue dropped 23% year-over-year.…

View full portfolio
Editorial model selection. Not personalised advice.